Kenvue

Kenvue is owned by its public shareholders who trade the company's stock on the New York Stock Exchange under the ticker symbol KVUE. While Kenvue was spun off from Johnson & Johnson in 2023, it now operates as an independent, publicly traded company with no parent organization or controlling shareholder. Investors can purchase shares in Kenvue to gain exposure to the consumer health market and the company's portfolio of iconic over-the-counter brands.

Yes, Kenvue is publicly traded on the New York Stock Exchange under the ticker symbol KVUE. The company began trading as a standalone public company in May 2023 following its spin-off from Johnson & Johnson, raising $3.8 billion in the largest U.S. IPO since 2021, with an initial valuation of about $41 billion. The company was subsequently added to the S&P 500 Dividend Aristocrats index, reflecting its strong dividend-paying history and market position.

Kenvue was founded in 2023 through a strategic spin-off from Johnson & Johnson. The spin-off was completed in August 2023, with Kenvue beginning operations as a standalone public company. The company was created to operate independently as a focused consumer health company, allowing Johnson & Johnson to concentrate on its pharmaceutical and medical device businesses while Kenvue focuses on over-the-counter health and wellness products.

Kirk Perry serves as the Chief Executive Officer of Kenvue. Perry was named interim CEO in 2025 following the termination of previous CEO Thibaut Mongon, and was subsequently named as the permanent CEO in November 2025. Under Perry's leadership, Kenvue has focused on four operating priorities to drive improved performance: operational efficiency, brand innovation, market expansion, and digital transformation.

Kenvue manufactures and markets over-the-counter health and wellness products across multiple categories including pain relief, oral care, wound care, skincare, digestive health, and allergy relief. The company's iconic brands include Tylenol (pain relief), Listerine (oral care), Band-Aid (wound care), Neutrogena (skincare), Aveeno (skincare), Motrin (pain relief), Imodium (digestive health), and Pepcid (digestive health), serving millions of consumers globally.

Kenvue is headquartered in Summit, New Jersey, USA, after relocating from the Skillman section of Montgomery Township, New Jersey. The company is incorporated in Delaware and maintains manufacturing facilities, research and development centers, and distribution networks across multiple countries including the United States, Europe, and Asia to support its global consumer health operations.

Kenvue holds the position of the world's largest pure-play consumer health company by revenue, with a portfolio of iconic over-the-counter brands that serve millions of consumers globally. The company maintains strong market positions in pain relief, oral care, wound care, and skincare categories, benefiting from decades of brand building and consumer trust established under Johnson & Johnson's stewardship.

In 2025, Kenvue demonstrated operational efficiency improvements with Q3 gross profit margin expanding 60 basis points to 59.1% and adjusted gross profit margin expanding 50 basis points to 61.2%, reflecting savings from productivity gains attributable to global supply chain optimization initiatives. The company appointed Kirk Perry as permanent CEO and affirmed its full-year 2025 outlook with adjusted diluted earnings per share expected to be in the range of $1.00 to $1.05.

Kenvue's portfolio includes iconic consumer health brands: Tylenol (pain relief and fever reduction), Listerine (oral care and mouthwash), Band-Aid (wound care and bandages), Neutrogena (skincare and personal care), Aveeno (skincare and personal care), Motrin (pain relief and anti-inflammatory), Imodium (digestive health), and Pepcid (digestive health). These brands represent one of the most comprehensive consumer health portfolios in the industry.

For the full year 2025, Kenvue affirmed its outlook with net sales and organic sales expected to be down low-single-digits, adjusted operating income margin expected to decline year-over-year, and adjusted diluted earnings per share expected to be in the range of $1.00 to $1.05, including a low-single-digit unfavorable impact from foreign currency. The company remains focused on executing its strategic priorities while navigating market challenges in the competitive global consumer health market.